EMA cuts MHRA out of drug reviews ahead of Brexit
04-09-2018
No-deal Brexit: MHRA would take on EMA functions for UK
24-08-2018
Parliament votes for UK to stay in EMA
23-07-2018
London loses EMA to Amsterdam
21-11-2017
artjazz / iStockphoto.com
The European Medicines Agency (EMA) has announced plans to temporarily further scale back and suspend activities in order to cope with a more significant staff loss from the agency’s relocation than was originally expected.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
Cooley
European Patent Office
Finnegan LLP
GH Research
Gowling WLG
George Washington Law School
HGF Limited
IQVIA
Kirkland & Ellis International LLP
Marks & Clerk
Mintz Levin
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
Taylor Wessing
The United States Patent and Trademark Office (USPTO)
Valea AB
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at achoudhury@newtonmedia.co.
If you have any technical issues please email tech support.
EMA, European Medicines Agency, Brexit, public health, animal health, big pharma, regulation
